Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: Efficacy, safety, and the association of the BRAF mutation

Laryngoscope

Volumn 122, Issue 7, 2012, Pages 1634-1640

  Tufano, Ralph P ^a   Bishop, Justin ^a   Wu, Gaosong ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; central neck dissection; mutation; Recurrent persistent papillary thyroid cancer; vocal fold paralysis

Indexed keywords

B RAF KINASE; CALCIUM; VITAMIN D;

ADOLESCENT; ADULT; AGED; CALCIUM BLOOD LEVEL; CANCER SURGERY; CONTROLLED STUDY; DEMOGRAPHY; DISSECTION; HUMAN; HYPOCALCEMIA; LARYNGOSCOPY; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MUTATION; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE; RECURRENT LARYNGEAL NERVE INJURY; REOPERATION; REOPERATIVE CENTRAL COMPARTMENT DISSECTION; RETROSPECTIVE STUDY; REVIEW; THERAPY EFFECT; THYROID PAPILLARY CARCINOMA; TUMOR RECURRENCE; VOCAL CORD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS B-RAF; REOPERATION; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84862867061     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23371     Document Type: Review

References (42)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR,. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998; 83: 2638-2648.
2. Paterson IC, Greenlee R, Adams Jones D,. Thyroid cancer in Wales 1985-1996: a cancer registry-based study. Clin Oncol (R Coll Radiol) 1999; 11: 245-251.
3. Davies L, Welch HG,. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
4. Leenhardt L, Grosclaude P, Cherie-Challine L,; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14: 1056-1060.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR,. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999; 86: 538-544.
6. Mazzaferri EL, Jhiang SM,. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
7. Caron NR, Clark OH,. Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol 2005; 6: 311-322.
8. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
9. White ML, Gauger PG, Doherty GM,. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31: 895-904.
10. Low TH, Delbridge L, Sidhu S, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol 2008; 15: 2827-2832.
11. Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg 2010; 145: 272-275.
12. Xing M,. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762.
13. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009; 27: 2977-2982.
14. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 19: 2322-2329.
15. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
16. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004; 10: 2761-2765.
17. Pai SI, Tufano RP,. Reoperation for recurrent/persistent well-differentiated thyroid cancer. Otolaryngol Clin North Am 2010; 43: 353-363.
18. Gharib H, Papini E, Paschke R, et al.; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest 2010; 33: 1-50.
19. Pai SI, Tufano RP,. Central compartment neck dissection for thyroid cancer. Technical considerations. ORL J Otorhinolaryngol Relat Spec 2008; 70: 292-297.
20. Farrag TY, Agrawal N, Sheth S, et al. Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma. Head Neck 2007; 29: 1069-1074.
21. Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 2008; 158: 551-560.
22. Balazs G, Gyory F, Lukacs G, Szakall S,. Long-term follow-up of node-positive papillary thyroid carcinomas. Langenbecks Arch Surg 1998; 383: 180-182.
23. Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 1988; 104: 954-962.
24. Lundgren CI, Hall P, Dickman PW, Zedenius J,. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006; 106: 524-531.
25. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V,. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992; 164: 658-661.
26. Shaha AR, Jaffe BM,. Parathyroid preservation during thyroid surgery. Am J Otol 1998; 109: 568-574.
27. Wingert DJ, Friesen SR, Illiopoulos JI, et al. Post-thyroidectomy hypocalcemia: incidence and risk factors. Am J Surg 1986; 152: 606-610.
28. Levin KE, Clark AH, Duh QY, et al. Reoperative thyroid surgery. Surgery 1992; 111: 604-607.
29. Chao TC, Jeng LB, Lin JD, Chen MF,. Reoperative thyroid surgery. World J Surg 1997; 21: 644-647.
30. Kasemsuwan L, Nubthuenetr S,. Recurrent laryngeal nerve paralysis: a complication of thyroidectomy. J Otolaryngol 1997; 26: 365-367.
31. Wagner HE, Seiler C,. Recurrent laryngeal nerve palsy after thyroid gland surgery. Br J Surg 1994; 81: 226-228.
32. Tisell LE, Hansson G, Jansson S, Salander H,. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986; 99: 60-66.
33. Goretzki P, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 1993; 80: 1009-1012.
34. Patou CA, Norton JA, Brennan MF,. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg 1998; 22: 718-724.
35. Wilson DB, Staren ED, Prinz RA,. Thyroid reoperations: indications and risks. Am Surg 1998; 64: 674-678.
36. Mazzaferri EL, Doherty GM, Steward DL,. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009; 19: 683-689.
37. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-4397.
38. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-5404.
39. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY,. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818-821.
40. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414-2420.
41. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61: 239-243.
42. Moley JF, Lairmore TC, Doherty GM, Brunt LM, DeBenedetti MK,. Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations. Surgery 1999; 125: 673-679.